A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)

NCT07247084 · Recruiting

Last updated 2026-05-28

This clinical trial is testing the medication tirzepatide against standard obesity treatments in adults with obesity who do not have diabetes to see how it affects body weight.

Status Recruiting Currently enrolling participants.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 3,000 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-11 · est. completion 2032-07

Where 30 sites · United Kingdom

What this study is testing ClinicalTrials.gov NCT07247084 ↗

Description as written by the study sponsor.

The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid condition. Participation in the study will last about 260 weeks.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
Standard of Care Other

Standard of care

Main thing measured	Percent Change from Baseline in Body Weight
Sponsor	Eli Lilly and Company
Conditions studied	Obesity
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07247084 ↗